Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis

  • Fernando M. Runzer-Colmenares
  • , Rossana Ruiz
  • , Lorenzo Maco
  • , Mike Maldonado
  • , Luis Puma-Villanueva
  • , Marco Galvez-Nino
  • , Carlos Aliaga
  • , Vicente A. Benites-Zapata
  • , Carlos Diaz-Arocutipa
  • , Luis Mas
  • , Diego Urrunaga-Pastor

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science